15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 1 of 15


Novartis (NYSE:NVS)

Consensus Rating
Rating Score
Ratings Breakdown
1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$114.00 (17.2% Upside)

About Novartis

Novartis logoNovartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Read More 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
2/23/2024BMO Capital MarketsInitiated CoverageMarket Perform$114.00
1/23/2024Morgan StanleyInitiated CoverageEqual Weight$114.00
12/18/2023HSBCDowngradeBuy ➝ Hold
9/25/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight
7/14/2023HSBCInitiated CoverageBuy
4/26/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
4/19/2023BTIG ResearchBoost Price Target$75.00 ➝ $85.00
3/27/2023Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold
1/26/2023CitigroupDowngradeBuy ➝ Neutral
1/6/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight

The only defense company you should be looking at (Ad)

This is the ONLY defense company you should be watching right now.

Get all the info here >>>